How biotechs can scale faster amid industry challenges

Since 2013, scaling biotech companies — early-stage and fast-growing companies — have brought two-thirds of new therapies to market, and, with billions of dollars of capital deployed into the life sciences sector, the opportunities for positive clinical impact are larger than ever before. Because of this massive and fast growth, these biotech and biopharma companies face specific challenges when it comes to space and infrastructure needs.

JLL’s free guide